Corrigendum to ``Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats'' [Current Therapeutic Research Volume 95, 2021, 100647]

• Mohammed Fouad Shalaby,
• Hekma A. Abd El Latif,
• Mohamed El Yamani,
• May Ahmed Galal,
• Sherifa Kamal,
• Ikhlas Sindi

Affiliations

Mohammed Fouad Shalaby

Pharmaceutical Sciences Department, Pharmacy Programme, Batterjee Medical College, Jeddah, Kingdom of Saudi Arabia; Corresponding author: Pharmaceutical Sciences Department, Pharmacy Programme, Batterjee Medical College, 21442, Jeddah, Kingdom of Saudi Arabia

Hekma A. Abd El Latif

Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Mohamed El Yamani

Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt

May Ahmed Galal

Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Sherifa Kamal

Pharmacology Department, National Organization for Drug Control and Research, Giza, Egypt

Ikhlas Sindi

Department of Biotechnology, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia